Femasys (NASDAQ: FEMY) director receives 102,366 Series D-1 stock warrants

Rhea-AI Filing Summary

Femasys Inc. director Kenneth D. Eichenbaum received 102,366 Series D-1 warrants as a non-cash award. These derivative securities allow him to acquire 102,366 shares of common stock at an exercise price of $0.58 per share, exercisable from March 19, 2026 until March 19, 2036. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement and are subject to exercise limitations under Nasdaq Capital Market rules.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Eichenbaum Kenneth D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Warrants	102,366	$0.00	--

Holdings After Transaction: Series D-1 Warrants — 102,366 shares (Direct)

Footnotes (1)

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eichenbaum Kenneth D.

(Last) (First) (Middle)

C/O FEMASYS INC.

3950 JOHNS CREEK COURT, SUITE 100

(Street)

SUWANEE GEORGIA 30024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Warrants	$0.58(1)	03/19/2026		A		102,366		03/19/2026	03/19/2036	Common stock, par value $0.001 per share	102,366(2)	(3)	102,366	D

Explanation of Responses:

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

2. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

3. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

	/s/ Kathy Lee-Sepsick, Attorney-in-fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Femasys Inc. (FEMY) report for Kenneth D. Eichenbaum?

Femasys reported that director Kenneth D. Eichenbaum received 102,366 Series D-1 warrants. These warrants were granted as consideration in a private placement tied to an Omnibus Amendment and Consent Agreement dated March 19, 2026.

What are the key terms of the Series D-1 warrants reported for FEMY?

The Series D-1 warrants let the holder purchase 102,366 Femasys common shares at an exercise price of $0.58 per share. They became exercisable on March 19, 2026 and expire on March 19, 2036, with customary anti-dilution adjustments.

How were the Series D-1 warrants to Kenneth D. Eichenbaum issued by Femasys (FEMY)?

The reported Series D-1 warrants were issued to Kenneth D. Eichenbaum in a private placement. They were granted as consideration in connection with an Omnibus Amendment and Consent Agreement among Femasys, Eichenbaum, and other parties dated March 19, 2026.

Are there any restrictions on exercising the FEMY Series D-1 warrants?

Yes. The holder’s ability to exercise the Series D-1 warrants for Femasys common stock is subject to certain limitations. These limitations are described as being in accordance with rules of the Nasdaq Capital Market.

What happens to the FEMY Series D-1 warrant exercise price over time?

The initial exercise price is $0.58 per share of Femasys common stock. This price is subject to adjustment under the warrant terms for events such as stock splits, stock dividends, stock combinations, recapitalizations, or similar corporate transactions.